HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a genetic test spare young breast cancer patients from chemo?
Disease control Not yet recruitingThis study looks at whether a genetic test (Prosigna®) can help decide if younger women with a common type of early breast cancer need chemotherapy. About 3380 premenopausal women will be randomly assigned to either standard treatment (always chemo plus hormone therapy) or a test…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New hope for breast cancer patients with brain tumors: combining radiation and targeted drugs
Disease control Not yet recruitingThis study tests whether adding a targeted drug (dalpiciclib) and hormone therapy to brain radiation can help control breast cancer that has spread to the brain. About 46 women with HR-positive, HER2-negative advanced breast cancer will receive the combination treatment. The goal…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Not yet recruitingThis study tests a new drug, BGB-43395, combined with letrozole against standard CDK4/6 inhibitor combinations in people with advanced or metastatic HR+/HER2- breast cancer who haven't had prior treatment for advanced disease. The goal is to see if the new combo works better at d…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Radiation plus Chemo-Immunotherapy shows promise in High-Risk breast cancer trial
Disease control Not yet recruitingThis study tests whether adding targeted radiation to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common, high-risk breast cancer type (HR+/HER2-). About 302 participants will receive either chemo-immunotherapy alone or with radia…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated May 07, 2026 18:41 UTC